Mongolian medicine composition for treating hepatitis B and preparation method thereof

Abstract

The invention provides a Mongolian medicine composition for treating hepatitis B and a preparation method of the Mongolian medicine composition. The composition is prepared from the following components in parts by weight: 75 to 85 parts of saffron, 75 to 85 parts of trogopterus dung, 65 to 75 parts of gardenia jasminoides, 45 to 55 parts of cortex phellodendri, 45 to 55 parts of dianthus chinensis, 55 to 65 parts of gypsum, 55 to 65 parts of scabiosa, 55 to 65 parts of calamine, 55 to 65 parts of caulis akebiae, 25 to 35 parts of rhizoma coptidis, 25 to 35 parts of fructus gardeniae, 25 to 35 parts of calomel, 25 to 35 parts of bunge corydalis herb, 45 to 55 parts of elecampane, 45 to 55 parts of rose and 55 to 65 parts of calculus bovis factitius. The Mongolian medicine composition for treating hepatitis B is prepared from multiple raw materials, meanwhile, the added coptis chinensis and rose flowers are treated through a specific extraction mode and a specific fermentation mode, and the prepared Mongolian medicine composition for treating hepatitis B has an excellent hepatitis B treatment effect.

Description

Technical Field

[0001] The invention belongs to the technical field of Mongolian medicine for treating hepatitis B, and particularly relates to a Mongolian medicine composition for treating hepatitis B and a preparation method thereof. Background Art

[0002] Hepatitis B (HBV) is an infectious disease caused by the hepatitis B virus (HBV), primarily affecting the liver and posing a serious threat to human health. Globally, there are approximately 257 million people with chronic HBV infection. In my country, the hepatitis B surface antigen (HBsAg) carrier rate is approximately 6.1%, representing a significant patient base. If untreated, HBV can progress to liver fibrosis, cirrhosis, and even liver cancer, leading to liver failure and death.

[0003] Currently, treatments for hepatitis B primarily include nucleoside (acid) analogue (NA) antiviral therapy and interferon therapy. NA drugs, such as entecavir and tenofovir disoproxil fumarate, can effectively inhibit viral replication, but they require long-term use, are prone to relapse after discontinuation, and may pose drug resistance issues. Interferon therapy, while having both immunomodulatory and antiviral effects, is associated with numerous adverse reactions, such as fever, chills, headache, muscle aches, and decreased white blood cells and platelets, resulting in poor patient tolerance. Furthermore, Western medicine treatments often focus solely on viral suppression, with little improvement in common hepatitis B patient symptoms such as fatigue, poor appetite, flank pain, and jaundice. Furthermore, it struggles to regulate the body's yin and yang balance and the overall flow of qi and blood.

[0004] The existing treatment of hepatitis B uses a combination of traditional Chinese medicines, which has little harm but poor effect. Based on this, the present invention improves and optimizes this in a targeted manner and proposes a Mongolian medicine composition for treating hepatitis B and a preparation method thereof. Summary of the Invention

[0005] In order to overcome the defects in the prior art, a Mongolian medicine composition for treating hepatitis B and a preparation method thereof are provided.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] A Mongolian medicine composition for treating hepatitis B comprises the following components, measured by mass: 75-85 parts of saffron, 75-85 parts of truncatum, 65-75 parts of truncatum chinense, 45-55 parts of phellodendron, 45-55 parts of lichen plantain, 55-65 parts of gypsum, 55-65 parts of blue pot flower, 55-65 parts of calamine, 55-65 parts of akebia, 25-35 parts of coptis chinensis, 25-35 parts of gardenia, 25-35 parts of calamine, 25-35 parts of calophyllum, 25-35 parts of philadelphus chinensis, 45-55 parts of elecampane, 45-55 parts of rose, and 55-65 parts of artificial bezoar.

[0008] Preferably, the coptis root in the Mongolian medicine composition is further processed by extraction, and the specific method is:

[0009] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0010] S2: adding 5-10% of the total amount of the coptis chinensis to the pretreated coptis chinensis, performing enzymatic hydrolysis to obtain coptis chinensis enzymatic hydrolyzed material;

[0011] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0012] Preferably, the enzyme material is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 40-45° C., and the enzymolysis time is 1 hour.

[0013] Preferably, the ethanol concentration of the ethanol-water extraction is 70-75 v / v%, the solid-liquid ratio is 4 kg: (40-45) L, the extraction temperature is 50-55° C., and the extraction time is 3 h.

[0014] Preferably, the fermentation extraction process of rose is carried out by the following method:

[0015] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0016] S12: Filter the fermented material through a 0.20 μm filter membrane, add 5-10% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0017] Preferably, the fermentation material is Lactobacillus bulgaricus.

[0018] Preferably, the fermentation temperature of the composite fermentation treatment is 38-42° C., and the fermentation time is 1 hour.

[0019] Preferably, the modified chitosan solution is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0020] Preferably, the mass fraction of the chitosan solution is 2-5%; the mass fraction of the sodium citrate solution is 5-8%.

[0021] Preferably, the method comprises the following steps: weighing raw materials according to weight, ball-milling the raw materials into powder, passing through 100 meshes, and bagging.

[0022] Compared with the prior art, the advantages and beneficial effects of the present invention are:

[0023] The Mongolian medicine composition for treating hepatitis B in the present application is prepared with multiple raw materials, and the coptis chinensis and rose flowers added are respectively processed by the specific extraction method and fermentation method of the present invention. The prepared Mongolian medicine composition for treating hepatitis B has excellent hepatitis B treatment effect. DETAILED DESCRIPTION

[0024] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0025] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components, measured by mass: 75-85 parts of saffron, 75-85 parts of aconite, 65-75 parts of twig buds, 45-55 parts of phellodendron, 45-55 parts of stone column flower, 55-65 parts of gypsum, 55-65 parts of blue pot flower, 55-65 parts of calamine, 55-65 parts of akebia, 25-35 parts of coptis chinensis, 25-35 parts of gardenia, 25-35 parts of light powder, 25-35 parts of bitter herb, 45-55 parts of elecampane, 45-55 parts of rose, and 55-65 parts of artificial bezoar.

[0026] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0027] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0028] S2: adding 5-10% of the total amount of the coptis chinensis to the pretreated coptis chinensis, performing enzymatic hydrolysis to obtain coptis chinensis enzymatic hydrolyzed material;

[0029] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0030] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 40-45° C., and the enzymolysis time is 1 hour.

[0031] The ethanol concentration of the ethanol-water extraction in this embodiment is 70-75 v / v%, the solid-liquid ratio is 4 kg: (40-45) L, the extraction temperature is 50-55° C., and the extraction time is 3 h.

[0032] The rose fermentation extraction process of this embodiment is as follows:

[0033] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0034] S12: Filter the fermented material through a 0.20 μm filter membrane, add 5-10% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0035] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0036] The fermentation temperature of the composite fermentation treatment in this embodiment is 38-42° C., and the fermentation is carried out for 1 hour.

[0037] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0038] The mass fraction of the chitosan solution in this embodiment is 2-5%; the mass fraction of the sodium citrate solution is 5-8%.

[0039] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0040] The present application is further described below with reference to specific embodiments, comparative examples, and analytical tests:

[0041] Example 1

[0042] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components in parts by mass: 75 parts of saffron, 75 parts of aconite, 65 parts of twig buds, 45 parts of phellodendron, 45 parts of stone stalk flowers, 55 parts of gypsum, 55 parts of blue pot flower, 55 parts of calamine, 55 parts of akebia, 25 parts of coptis chinensis, 25 parts of gardenia, 25 parts of light powder, 25 parts of bitter herb, 45 parts of inulin, 45 parts of rose, and 55 parts of artificial bezoar.

[0043] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0044] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0045] S2: adding 5% enzyme feed of the total amount of the Rhizoma Coptidis to the pretreated Rhizoma Coptidis, performing enzymatic hydrolysis to obtain Rhizoma Coptidis enzymatic hydrolyzed material;

[0046] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0047] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 40° C., and the enzymolysis time is 1 hour.

[0048] The ethanol concentration of the ethanol-water extraction in this embodiment is 70 v / v%, the solid-liquid ratio is 4 kg:40 L, the extraction temperature is 50-55° C., and the extraction time is 3 h.

[0049] The rose fermentation extraction process of this embodiment is as follows:

[0050] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0051] S12: Filter the fermented material through a 0.20 μm filter membrane, add 5% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0052] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0053] The fermentation temperature of the composite fermentation treatment in this embodiment is 38° C., and the fermentation time is 1 hour.

[0054] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0055] The mass fraction of the chitosan solution in this embodiment is 2%; the mass fraction of the sodium citrate solution is 5%.

[0056] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0057] Example 2

[0058] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components in parts by mass: 85 parts of saffron, 85 parts of aconite, 75 parts of twig buds, 55 parts of phellodendron, 55 parts of stone stalk flowers, 65 parts of gypsum, 65 parts of blue pot flower, 65 parts of calamine, 65 parts of akebia, 35 parts of coptis chinensis, 35 parts of gardenia, 35 parts of light powder, 35 parts of bitter herb, 55 parts of inulin, 55 parts of rose, and 65 parts of artificial bezoar.

[0059] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0060] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0061] S2: adding 10% of the total amount of the coptis chinensis to the pretreated coptis chinensis, performing enzymatic hydrolysis to obtain coptis chinensis enzymatic hydrolyzed material;

[0062] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0063] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, and the enzymolysis temperature is 45° C. and the enzymolysis time is 1 hour.

[0064] The ethanol concentration of the ethanol-water extraction in this embodiment is 75 v / v%, the solid-liquid ratio is 4 kg:45 L, the extraction temperature is 50-55° C., and the extraction time is 3 h.

[0065] The rose fermentation extraction process of this embodiment is as follows:

[0066] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0067] S12: Filter the fermented material through a 0.20 μm filter membrane, add 10% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0068] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0069] The fermentation temperature of the composite fermentation treatment in this embodiment is 42° C., and the fermentation time is 1 hour.

[0070] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0071] The mass fraction of the chitosan solution in this embodiment is 5%; the mass fraction of the sodium citrate solution is 8%.

[0072] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0073] Example 3

[0074] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components in parts by mass: 80 parts of saffron, 80 parts of aconite, 70 parts of twig flower, 50 parts of phellodendron, 50 parts of stone column flower, 60 parts of gypsum, 60 parts of blue pot flower, 60 parts of calamine, 60 parts of akebia, 30 parts of coptis chinensis, 30 parts of gardenia, 30 parts of light powder, 30 parts of bitter herb, 50 parts of inulin, 50 parts of rose, and 60 parts of artificial bezoar.

[0075] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0076] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0077] S2: adding 7.5% enzyme feed of the total amount of the Rhizoma Coptidis to the pretreated Rhizoma Coptidis, performing enzymatic hydrolysis to obtain Rhizoma Coptidis enzymatic hydrolyzed feed;

[0078] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0079] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 42° C., and the enzymolysis time is 1 hour.

[0080] The ethanol concentration of the ethanol-water extraction in this example was 72.5 v / v%, the solid-liquid ratio was 4 kg:42.5 L, the extraction temperature was 52° C., and the extraction time was 3 h.

[0081] The rose fermentation extraction process of this embodiment is as follows:

[0082] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0083] S12: Filter the fermented material through a 0.20 μm filter membrane, add 7.5% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0084] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0085] The fermentation temperature of the composite fermentation treatment in this embodiment is 40° C. and the fermentation time is 1 hour.

[0086] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0087] The mass fraction of the chitosan solution in this embodiment is 3.5%; the mass fraction of the sodium citrate solution is 6.5%.

[0088] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0089] Example 4

[0090] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components in parts by mass: 77 parts of saffron, 76 parts of aconite, 68 parts of twig buds, 46 parts of phellodendron, 47 parts of stone column flower, 58 parts of gypsum, 58 parts of blue pot flower, 58 parts of calamine, 60 parts of akebia, 30 parts of coptis chinensis, 30 parts of gardenia, 28 parts of light powder, 28 parts of bitter herb, 48 parts of inulin, 49 parts of rose, and 58 parts of artificial bezoar.

[0091] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0092] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0093] S2: adding 6% enzyme feed of the total amount of the Rhizoma Coptidis to the pretreated Rhizoma Coptidis, performing enzymatic hydrolysis to obtain Rhizoma Coptidis enzymatic hydrolyzed feed;

[0094] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0095] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 42° C., and the enzymolysis time is 1 hour.

[0096] The ethanol concentration of the ethanol aqueous solution extracted in this example is 72 v / v%, the solid-liquid ratio is 4 kg:42 L, the extraction temperature is 52° C., and the extraction time is 3 h.

[0097] The rose fermentation extraction process of this embodiment is as follows:

[0098] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0099] S12: Filter the fermented material through a 0.20 μm filter membrane, add 6% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0100] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0101] The fermentation temperature of the composite fermentation treatment in this embodiment is 40° C. and the fermentation time is 1 hour.

[0102] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0103] The mass fraction of the chitosan solution in this embodiment is 3%; the mass fraction of the sodium citrate solution is 6%.

[0104] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0105] Example 5

[0106] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components, measured by mass: 83 parts of saffron, 83 parts of aconite, 72 parts of twig bud flower, 52 parts of phellodendron, 52 parts of stone column flower, 62 parts of gypsum, 63 parts of blue pot flower, 64 parts of calamine, 62 parts of akebia, 32 parts of coptis chinensis, 32 parts of gardenia, 30 parts of light powder, 32 parts of bitter herb, 52 parts of inulin, 55 parts of rose, and 63 parts of artificial bezoar.

[0107] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0108] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0109] S2: adding 9% enzyme feed of the total amount of the Rhizoma Coptidis to the pretreated Rhizoma Coptidis, performing enzymatic hydrolysis to obtain Rhizoma Coptidis enzymatic hydrolyzed material;

[0110] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0111] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, and the enzymolysis temperature is 44° C. and the enzymolysis time is 1 hour.

[0112] The ethanol concentration of the ethanol aqueous solution extracted in this example is 74 v / v%, the solid-liquid ratio is 4 kg:42 L, the extraction temperature is 54° C., and the extraction time is 3 h.

[0113] The rose fermentation extraction process of this embodiment is as follows:

[0114] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0115] S12: Filter the fermented material through a 0.20 μm filter membrane, add 8% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0116] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0117] The fermentation temperature of the composite fermentation treatment in this embodiment is 40° C. and the fermentation time is 1 hour.

[0118] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0119] The mass fraction of the chitosan solution in this embodiment is 4%; the mass fraction of the sodium citrate solution is 7%.

[0120] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0121] Example 6

[0122] In the present application, a Mongolian medicine composition for treating hepatitis B includes the following components in parts by mass: 77 parts of saffron, 84 parts of aconite, 72 parts of twig bud, 53 parts of phellodendron, 47 parts of stone column flower, 58 parts of gypsum, 62 parts of blue pot flower, 62 parts of calamine, 58 parts of akebia, 29 parts of coptis chinensis, 32 parts of gardenia, 233 parts of light powder, 32 parts of bitter herb, 46 parts of inulin, 48 parts of rose, and 58 parts of artificial bezoar.

[0123] The Mongolian medicine composition of the present embodiment is also processed by extracting the coptis root, and the specific method is as follows:

[0124] S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis;

[0125] S2: adding 5-10% of the total amount of the coptis chinensis to the pretreated coptis chinensis, performing enzymatic hydrolysis to obtain coptis chinensis enzymatic hydrolyzed material;

[0126] S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

[0127] The enzyme material of this embodiment is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 42° C., and the enzymolysis time is 1 hour.

[0128] The ethanol concentration of the ethanol aqueous solution extracted in this example is 74 v / v%, the solid-liquid ratio is 4 kg:44 L, the extraction temperature is 52° C., and the extraction time is 3 h.

[0129] The rose fermentation extraction process of this embodiment is as follows:

[0130] S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material;

[0131] S12: Filter the fermented material through a 0.20 μm filter membrane, add 8% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

[0132] The fermentation material of the present embodiment is Lactobacillus bulgaricus.

[0133] The fermentation temperature of the composite fermentation treatment in this embodiment is 40° C. and the fermentation time is 1 hour.

[0134] The modified chitosan solution of this embodiment is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

[0135] The mass fraction of the chitosan solution in this embodiment is 3%; the mass fraction of the sodium citrate solution is 7%.

[0136] The present embodiment comprises the following steps: weighing raw materials according to weight, ball-grinding the raw materials into powder, passing through 100 mesh, and bagging.

[0137] Comparative Example 1

[0138] In this comparative example, the same points as in Example 1 are not repeated here, and the differences are as follows:

[0139] No coptis root added.

[0140] Comparative Example 2

[0141] In this comparative example, the same points as in Example 1 are not repeated here, and the differences are as follows:

[0142] The S2 step was not used in the extraction of Coptis chinensis.

[0143] Comparative Example 3

[0144] In this comparative example, the same points as in Example 1 are not repeated here, and the differences are as follows:

[0145] No rose petals added.

[0146] Comparative Example 4

[0147] In this comparative example, the same points as in Example 1 are not repeated here, and the differences are as follows:

[0148] Modified chitosan solution was not used in rose.

[0149] Table 1 Performance test results of the compositions under different conditions

[0150]

[0151] As can be seen from Table 1,

[0152] The technical solution of the present invention shows significant advantages in core performances such as HBSAg inhibition rate and HBeAg, and the selection of process parameters (such as S2 step processing) directly affects the final effect. The specific preparation conditions of Coptis chinensis and Rose also verify the innovativeness of the synergistic optimization of formula and process; multiple functional breakthroughs are achieved through innovative formula and process optimization, and the product performance effect is significant through the synergistic effect of the coordination between raw materials.

[0153] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A Mongolian medicine composition for treating hepatitis B, characterized in that: The composition includes the following components in parts by mass: 75-85 parts of saffron, 75-85 parts of truncatum, 65-75 parts of truncatum chinense, 45-55 parts of phellodendron, 45-55 parts of stone column flower, 55-65 parts of gypsum, 55-65 parts of blue pot flower, 55-65 parts of calamine, 55-65 parts of akebia, 25-35 parts of coptis chinensis, 25-35 parts of gardenia, 25-35 parts of talcum powder, 25-35 parts of bitter herb, 45-55 parts of elecampane, 45-55 parts of rose, and 55-65 parts of artificial bezoar.

2. A Mongolian medicine composition for treating hepatitis B according to claim 1, characterized in that: The coptis root in the Mongolian medicine composition is also processed by extraction, and the specific method is: S1: grinding the raw material of Coptis chinensis, and then soaking the Coptis chinensis in hot water to obtain pretreated Coptis chinensis; S2: adding 5-10% of the total amount of the coptis chinensis to the pretreated coptis chinensis, performing enzymatic hydrolysis to obtain coptis chinensis enzymatic hydrolyzed material; S3: The enzymatic hydrolyzed material of Coptis chinensis is extracted with an ethanol aqueous solution, and then the supernatant is collected by centrifugation, and then freeze-dried to obtain Coptis chinensis.

3. A Mongolian medicine composition for treating hepatitis B according to claim 2, characterized in that: The enzyme material is a compound of cellulase and pectinase in a weight ratio of 3:2, the enzymolysis temperature is 40-45° C., and the enzymolysis time is 1 hour.

4. A Mongolian medicine composition for treating hepatitis B according to claim 2, characterized in that: The ethanol concentration of the ethanol-water extraction is 70-75 v / v%, the solid-liquid ratio is 4 kg: (40-45) L, the extraction temperature is 50-55° C., and the extraction time is 3 h.

5. A Mongolian medicine composition for treating hepatitis B according to claim 1, characterized in that: The rose fermentation extraction process is specifically performed as follows: S11: fermenting the roses and the fermentation material in a weight ratio of 8:1 to obtain a fermentation material; S12: Filter the fermented material through a 0.20 μm filter membrane, add 5-10% of the modified chitosan solution to the filtrate, stir evenly, filter and dry.

6. A Mongolian medicine composition for treating hepatitis B according to claim 5, characterized in that: The fermentation material is Lactobacillus bulgaricus.

7. A Mongolian medicine composition for treating hepatitis B according to claim 5, characterized in that: The fermentation temperature of the composite fermentation treatment is 38-42° C., and the fermentation time is 1 hour.

8. A Mongolian medicine composition for treating hepatitis B according to claim 5, characterized in that: The modified chitosan solution is prepared by uniformly blending chitosan solution, sodium citrate solution and sodium silicate in a weight ratio of 3:2:1 to obtain the modified chitosan solution.

9. A Mongolian medicine composition for treating hepatitis B according to claim 8, characterized in that: The mass fraction of the chitosan solution is 2-5%; the mass fraction of the sodium citrate solution is 5-8%.

10. A method for preparing a Mongolian medicine composition for treating hepatitis B according to any one of claims 1 to 9, characterized in that: The following steps are involved: Weigh the raw materials according to weight, ball-grind them into powder, pass through 100 mesh, and bag them.

Images